MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Kodu・Aktsiate loetelu・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Suletud

SektorTervishoid

426.42 -1.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

417.21

Max

431.15

Põhinäitajad
By Trading Economics
Sissetulek	194M 1.8B
Müük	795M 11B
P/E Sektori keskmine	25.505 57.333
Aktsiakasum	6.1
Dividenditootlus	0.4
Kasumimarginaal	16.007
Töötajad	125,000
EBITDA	377M 3B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+32.5% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.40% 2.63%
Järgmine tulemuste avaldamine	23. juuli 2025
Järgmine dividendimakse kuupäev	14. juuli 2025
Järgmine aktsia dividendi kuupäev (ex-date)	13. juuni 2025

Turustatistika
By TradingEconomics
Turukapital	-67B 161B
Eelmine avamishind	427.76
Eelmine sulgemishind	426.42

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

426.51 / 427.44 Toetus ja vastupanu

Thermo Fisher Scientific Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2025, 10:33 UTC

Tulu

Thermo Fisher 1Q Net, Revenue Up, Costs Stable

25. veebr 2025, 14:05 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30. jaan 2025, 11:43 UTC

Tulu

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23. apr 2025, 10:01 UTC

Tulu

Thermo Fisher 1Q Adjusted Operating Margin 21.9% >TMO

23. apr 2025, 10:00 UTC

Tulu

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23. apr 2025, 10:00 UTC

Tulu

Thermo Fisher 1Q EPS $3.98 >TMO

23. apr 2025, 10:00 UTC

Tulu

Thermo Fisher 1Q Rev $10.36B >TMO

23. apr 2025, 10:00 UTC

Tulu

Thermo Fisher 1Q Adj EPS $5.15 >TMO

23. apr 2025, 10:00 UTC

Tulu

Thermo Fisher 1Q Net $1.51B >TMO

25. veebr 2025, 14:09 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25. veebr 2025, 13:41 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25. veebr 2025, 13:40 UTC

Omandamised, ülevõtmised, äriostud

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25. veebr 2025, 13:39 UTC

Omandamised, ülevõtmised, äriostud

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25. veebr 2025, 13:33 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25. veebr 2025, 13:32 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25. veebr 2025, 13:32 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24. veebr 2025, 23:03 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Deal Could be Announced This Week, Sources Say -- WSJ

24. veebr 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30. jaan 2025, 11:06 UTC

Tulu

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30. jaan 2025, 11:05 UTC

Tulu

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Rev $11.4B >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q EPS $4.78 >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Net $1.83B >TMO

30. jaan 2025, 11:00 UTC

Tulu

Thermo Fisher 4Q Adj EPS $6.10 >TMO

Võrdlus sarnastega

Hinnamuutus

Thermo Fisher Scientific Inc Prognoos

Hinnasiht

By TipRanks

32.5% tõus

12 kuu keskmine prognoos

Keskmine 565.32 USD 32.5%

Kõrge 650 USD

Madal 475 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Thermo Fisher Scientific Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Thermo Fisher Scientific Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

426.51 / 427.44Toetus ja vastupanu

Recent bullish events outweigh bearish events.

There are no events.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar